Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Orexo AB ( (SE:ORX) ) has issued an update.
Orexo AB reported a challenging second quarter of 2025, with total net revenues of SEK 118.2 million, impacted by currency headwinds and a non-recurring rebate payment. The company experienced a negative EBITDA of SEK -10.1 million and net earnings of SEK -39.8 million. Despite these financial challenges, Orexo announced positive in-vivo data for its intranasal vaccine developed with Abera Bioscience and presented clinical data for its OX640 intranasal rescue medication. The election of Friedrich von Bohlen as the new Chairman of the Board marks a significant leadership change.
More about Orexo AB
Orexo AB is a commercial-stage pharmaceutical company that develops drugs using cutting-edge drug delivery technologies. The company is committed to the UN Global Compact corporate responsibility initiative, focusing on human rights, labor, environment, and anti-corruption.
Average Trading Volume: 20,652
Current Market Cap: SEK663.3M
For an in-depth examination of ORX stock, go to TipRanks’ Overview page.